Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06557512
Status
Recruiting
Apply to this trial

Conditions

  • Meningioma
  • Meningioma, Malignant
  • Recurrent Meningioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hypofractionated Stereotactic Radiosurgery (SRS) — RADIATION
    Undergo Hypofractionated Stereotactic Radiosurgery
  • Magnetic Resonance Imaging (MRI) — PROCEDURE
    Undergo MRI
  • Computed Tomography (CT) — PROCEDURE
    Undergo CT imaging

Study Details

This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.

Key Dates

Start date
Dec 13, 2024
Status verified
May 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
23 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hypofractionated Stereotactic Radiosurgery (SRS)
    Participants undergo hypofractionated stereotactic radiosurgery over 15-30 minutes QD on days 1-5 in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Proportion of participants with reported adverse events [ Time Frame: Up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Francim Aguilar
[email protected]
[email protected]
877-827-3222
William Chen, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies